Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in biologic-naive nonradiographic axial spondyloarthritis
NL-OMON43074Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in non-radiographic axial spondyloarthritis (nr-axSpA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: ASAS40 response at Week 16. Started Aug 2016; status: active, not recruiting.
02
Drugs
ixekizumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NL-OMON43074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43074.